Related Experiment Videos
Calcium-sensing receptor and calcimimetic agents.
J W Coburn1, L Elangovan, W G Goodman
1Medical and Research Services, Veterans Affairs West Los Angeles Healthcare Center, California, USA.
Kidney International. Supplement
|January 14, 2000
Summary
The calcium-sensing receptor (CaR) regulates calcium homeostasis and mineral metabolism. Modulating CaR activity with calcimimetic drugs shows promise for treating hyperparathyroidism and related disorders.
Area of Science:
- Endocrinology
- Nephrology
- Molecular Biology
Background:
- The extracellular calcium-sensing receptor (CaR) is a G-protein-coupled receptor crucial for calcium homeostasis.
- CaR plays a vital role in regulating parathyroid hormone (PTH) secretion and renal calcium excretion.
- CaR dysfunction underlies various genetic and acquired disorders of mineral metabolism.
Purpose of the Study:
- To review the biology and physiological roles of the CaR.
- To discuss clinical disorders associated with CaR mutations and acquired abnormalities.
- To summarize the therapeutic potential of calcimimetic drugs targeting the CaR.
Main Methods:
- Literature review of CaR biology, physiology, and clinical implications.
- Analysis of clinical data and experiences with calcimimetic agents in hyperparathyroidism.
Main Results:
- CaR regulates PTH secretion and renal handling of calcium, magnesium, and water.
- CaR mutations cause familial hypocalciuric hypercalcemia and hereditary hypoparathyroidism.
- Calcimimetic drugs effectively lower PTH and calcium levels in hyperparathyroidism with a good safety profile.
Conclusions:
- The CaR is a key regulator of calcium-mineral balance.
- Dysregulation of CaR leads to significant clinical disorders.
- Calcimimetics represent a promising therapeutic strategy for CaR-related conditions, warranting further long-term studies.